Actively Recruiting
Phase 12 Study of Gabapentin and Intranasal Ketamine for Preventing and Treating Pain in Adults with Locally Advanced Head and Neck Cancer Undergoing Chemoradiation
Led by Natalie Lockney · Updated on 2024-10-21
64
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to find a safe and feasible dose for using a combination of gabapentin and ketamine to prevent and treat acute and chronic pain in patients with locally advanced head and neck cancer undergoing chemoradiation. The study focuses on determining the highest dose of ketamine that can be tolerated when combined with gabapentin, while also assessing the treatments feasibility and tolerability. Additionally, it explores effects on pain, symptom burden, functionality, and quality of life. Participants will take gabapentin by mouth and ketamine administered intranasally, both three times daily. The ketamine dose will be increased up to a planned maximum of 40 mg taken three times a day. This trial includes both Phase I and Phase II periods Phase I lasts about 28 days to establish the maximum tolerated ketamine dose, followed by Phase II which monitors adverse events up to 30 days after treatment. During the study, participants will be closely monitored for side effects and tolerability using standard criteria. Researchers will assess pain levels, symptoms, daily functioning, and overall quality of life throughout the treatment. The study involves regular evaluations to measure safety and treatment effects, with participation lasting through the treatment and follow-up periods as defined by each phase.
CONDITIONS
Brief Title
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Research Team
V
Vanderbilt-Ingram Service for Timely Access
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here